drugset / Press release
Ryzodeg® (insulin degludec/insulin aspart) approved in Japan
2012-12-25 · Novo Nordisk A/S · original novonordisk.com ↗
Degludec
Insulin
Insulin degludec/insulin aspart
Insulin degludec/insulin aspart
insulin aspart
insulin degludec
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
regular insulin
Bagsværd, Denmark, 25 December 2012 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ryzodeg® (insulin degludec/insulin aspart) for the treatment of diabetes. Further information Media: Mike Rulis +45 4442 3573 [email protected] Ambre Morley (US) +1 609 216 5240 [email protected] Investors: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company announcement No 84 /2012
The release as fetched from its publisher. novonordisk.com ↗